{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.95","upperLimit":"90.7","value":"6.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"description":"OS is defined as the time from the on-study date until date of death or last follow-up.","dispersionType":"Full Range","groups":[{"description":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m\\^2 intravenous (IV) (days 1-5); VX970 (M6620) 210mg/m\\^2 IV on day 2, 5.\n\nMaximum Tolerated Dose/Recommended Phase II Dose. Small cell lung cancer (SCLC) participants only.","id":"OG000","title":"Phase II Dose Level (DL) 4 Topotecan 1.25mg/m^2; VX970 (M6620) 210mg/m^2 Recommended Phase II Dose"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"On-study date until date of death, an average of 12.22 months.","title":"Phase II: Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Months"}